MEDICINA

2022

1. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

   Clinical cancer research : an official journal of the American Association for Cancer Research

2. A clozapine's uncharted voyage: Five years and a pandemic after the end of mandatory haematological notifications to the Spanish medicines agency

   Revista de Psiquiatria y Salud Mental

3. Acquired haemophilia A secondary to metastatic prostate cancer

   Medicina Clinica

4. Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma

   HemaSphere

5. Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension (Scientific Reports, (2022), 12, 1, (5289), 10.1038/s41598-022-09353-z)

   Scientific Reports

6. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19

   Blood Advances

7. Cancer and elderly: Two incompatible concepts for intensive care?

   Revista Espanola de Geriatria y Gerontologia

8. CardioVerse: Buying the stairway to heaven

   Trends in Cardiovascular Medicine

9. Characteristics, Acute Results, and Prognostic Impact of Percutaneous Coronary Interventions in Spontaneous Coronary Artery Dissection (from the Prospective Spanish Registry on SCAD [SR-SCAD])

   American Journal of Cardiology

10. Commentary: Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer

    Frontiers in Molecular Biosciences

11. Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis (Advances in Therapy, (2022), 39, 5, (1976-1992), 10.1007/s12325-022-02083-8)

    Advances in Therapy

12. Corrigendum

    Pain medicine (Malden, Mass.)

13. Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322

    Annals of oncology : official journal of the European Society for Medical Oncology

14. Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)

    Clinical Lymphoma, Myeloma and Leukemia

15. Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))

    Clinical Lymphoma, Myeloma and Leukemia

16. Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))

    Annals of Oncology

17. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

    American Journal of Hematology

18. Erratum to “Takotsubo syndrome and cancer, clinical and prognostic implications, insights of RETAKO” [Med Clin (Barc). 2020;155(12):521-528] (Medicina Clinica (2020) 155(12) (521–528), (S0025775320301895), (10.1016/j.medcli.2020.01.033))

    Medicina Clinica

19. Evaluation of Respiratory Sequelae in Patients With COVID-19, Where we are and Where we are Going. CIBERESUCICOVID and RECOVID Studies to Compare Patients Admitted to ICU vs Conventional Ward

    Archivos de Bronconeumologia

20. Familial hypocalciuric hypercalcemia. Concerning two cases

    Revista de Osteoporosis y Metabolismo Mineral